Loading…
← CockpitCompetitor Analysis › MEDANTA.NS Global HealthOpen in the cockpit ↗

Global HealthMEDANTA.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Hospital/Nursing Management

Gurugram-headquartered multi-specialty hospital chain (Medanta) offering tertiary/quaternary care across several Indian cities.

≈ India's Cleveland Clinic-style super-specialty hospital operatorMomentum strong 75
Mkt cap
$4.13B
US dollars, full cap
Free float
32%
of shares outstanding
$/day
$4.39M
20-day average traded
Fwd P/E
50.4×
forward earnings
ROIC−WACC
+3.5 pp
WACC 11.2%
Hurdle
n/a
no reverse DCF
Next earnings
84 days
10 Feb 2027
Close · INR₹1,437
1D-0.5%
1W+0.5%
1M+16.0%
3M-0.4%
6M+15.8%
YTD+21.1%
1Y+22.4%
ATR %3.0%
Beta0.71
52w lowhigh7.0% off high

What Global Health does

Gurugram-headquartered multi-specialty hospital chain (Medanta) offering tertiary/quaternary care across several Indian cities.

Charges patients for procedures, rooms and tests, with insurers, government schemes and self-paying patients all in the mix; profit rests on filling beds and operating theatres with complex cases. It grew around cardiac surgeon Naresh Trehan, with the Gurugram hospital as the flagship and newer hospitals in other cities still ramping up.

In one line: India's Cleveland Clinic-style super-specialty hospital operator.

Products and services

  • Cardiac sciences
  • Oncology, neurosciences, transplants
  • Multi-specialty general hospital care

Customers

  • Domestic patients
  • Medical tourism/international patients

Where it sits in the supply chain

  • Healthcare services
  • Hospital/tertiary care
  • Multi-specialty hospital chain

What could go right

  • Rising tertiary-care demand in India
  • Medical tourism growth

What could go wrong

  • High fixed-cost/capex intensity
  • Physician talent retention

Moat: narrow (brand, installed base). Reputation built on renowned physicians and large tertiary-care infrastructure.

Headquarters: Gurugram, India · Founded: 2004 · Employees: 14,777

Named competitors

Global Health at a glance

Size Global Health (MEDANTA.NS) is an India Health Care company (Hospital/Nursing Management) with a market value of $4.13B, the 236th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,437 on 18 Nov 2026.

Performance Over six months the shares gained 15.8%, against +0.4% for the median peer and +3.8% for the India market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 26.2% over the last twelve months (peer median +9.5%); the operating margin is 16.8% (peer median 10.9%).

Valuation It trades at 50.4× forward earnings against a peer median of 37.5× (8th most expensive of 19).

Capital Return on invested capital runs 3.5 points above its cost of capital (11.2% WACC).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011012021 May 202621 Aug 202618 Nov 2026MEDANTA.NS 116Peer median 99
Six months, rebased to 100: Global Health against the median of its 20 peers (local-currency closes).

Global Health financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹50.5B₹43.3B₹36.5B₹32.5B₹26.9B
Revenue growth—+19%+12%+21%—
Gross profit₹24.5B₹18.4B₹16.0B₹14.5B₹11.5B
EBITDA₹11.2B₹8.71B₹8.56B₹8.28B₹6.42B
Net income₹6.18B₹5.56B₹4.81B₹4.78B₹3.26B
Free cash flown/a-₹2.25B₹177M₹3.61B₹3.81B
Capital expendituren/a₹9.79B₹6.48B₹2.79B₹2.36B
Total debt₹13.5B₹11.9B₹7.18B₹8.02B₹11.2B

Quarterly statements and history in the cockpit →

Global Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%0%+50%NHSGRYKIMSNHCFORTISCHE600763PACSBKDRHCARDT301267MAXHEALTHUHSSIAAEVSMEDANTA.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Global Health is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×200×400×NHSGRYKIMSFORTISASTERDMCHE600763BKDEXEMANIPALHOSMAXHEALTHAEVSMEDANTA.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Global Health is the large dot.

Global Health competitors and peer comparison

Head to head with its named competitors (MEDANTA.NS vs APOLLOHOSP.NS vs MAXHEALTH.NS vs FORTIS.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Global Health MEDANTA.NS$4.13B+16%+26%17%50.4×n/a
Apollo Hospitals Enterprise APOLLOHOSP.NS$13.6B+10%+19%12%51.0×33.3%
Max Healthcare Institute MAXHEALTH.NS$10.6B-4%+15%21%55.2×45.3%
Fortis Healthcare FORTIS.NS$6.40B-17%+18%17%48.5×42.5%
Narayana Hrudayalaya NH.NS$4.13B0%+71%13%34.2×31.2%

How Global Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Global Health against its 20 peers (data as of 18 Nov 2026)
MeasureMEDANTA.NSPeer medianRank in peer set
1-month return+16.0%+5.4%4th highest of 21
6-month return+15.8%+0.4%6th highest of 20
Distance from 52-week high-7.0%-16.7%4th highest of 21
Revenue growth (TTM)+26.2%+9.5%5th highest of 21
Operating margin16.8%10.9%5th highest of 21
Forward P/E50.4×37.5×8th most expensive of 19
ROIC minus cost of capital+3.5 pp-2.5 pp4th highest of 21
EV / EBITDA34.5×18.3×5th most expensive of 16
Net debt / EBITDA-0.0×3.0×least indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Global Health MEDANTA.NSIndia$4.13B+16%+26%17%50.4×n/an/a
Narayana Hrudayalaya NH.NSIndia$4.13B0%+71%13%34.2×31.2%+25.0%
Surgery Partners SGRYUnited States$3.53B+100%+2%13%77.2×15.6%+12.2%
Krishna Institute of Medical Sciences KIMS.NSIndia$3.41B+2%+35%11%81.9×n/an/a
National HealthCare NHCUnited States$3.16B+1%+6%0%n/a6.4%+9.7%
Fortis Healthcare FORTIS.NSIndia$6.40B-17%+18%17%48.5×42.5%+17.9%
Aster DM Quality Care ASTERDM.NSIndia$6.83B-2%+50%16%63.5×48.6%-11.6%
Chemed CHEUnited States$7.12B+24%+5%14%20.2×3.3%+4.0%
Topchoice Medical 600763.SSChina$2.33B-12%+7%26%24.8×12.4%+6.9%
PACS PACSUnited States$7.35B+25%+11%8%17.5×7.5%+29.7%
Brookdale Senior Living BKDUnited States$2.06B-36%-8%6%482.6×19.3%-1.4%
Ramsay Health Care RHC.AXAustralia$8.31B+41%+4%5%31.4×14.0%+8.3%
Ardent Health ARDTUnited States$2.03B+52%+2%5%11.9×-1.7%+8.7%
Extendicare EXE.TOCanada$1.91B-16%+36%9%19.3×10.8%+8.5%
Huaxia Eye Hospital 301267.SZChina$1.78B-18%+2%15%23.5×2.1%+10.4%
Manipal Health Enterprises MANIPALHOS.NSIndia$9.69Bn/a+25%19%66.5×32.9%+28.8%
Max Healthcare Institute MAXHEALTH.NSIndia$10.6B-4%+15%21%55.2×45.3%+27.2%
Universal Health Services UHSUnited States$10.7B+13%+8%11%8.3×-1.8%+8.5%
Sienna Senior Living SIA.TOCanada$1.58B-8%+15%10%40.9×18.9%+8.6%
Xi'an International Medical Investment 000516.SZChina$1.46B-2%-1%-2%n/a12.7%+20.6%
Aevis Victoria AEVS.SWSwitzerland$1.43B+8%+15%-6%106.8×26.5%+10.2%

Questions

Who are Global Health's main competitors?
Named competitors: Apollo Hospitals (APOLLOHOSP.NS), Max Healthcare (MAXHEALTH.NS), Fortis Healthcare (FORTIS.NS), Narayana Hrudayalaya (NH.NS). The cockpit's measured peer set (industry) also includes Narayana Hrudayalaya (NH.NS), Surgery Partners (SGRY), Krishna Institute of Medical Sciences (KIMS.NS), National HealthCare (NHC), Fortis Healthcare (FORTIS.NS), Aster DM Quality Care (ASTERDM.NS).
Is Global Health expensive compared with its peers?
On forward p/e it trades at 50.4× against a peer median of 37.5×, 8th most expensive of 19 in its peer set.
How has Global Health stock performed?
Over six months to 18 Nov 2026 the shares returned +15.8% against +0.4% for the median peer; over one year +22.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.